Scholar Rock is removing Catalent Indiana as a fill-finish facility for its apitegromab BLA after the FDA classified Catalent's inspection as Official Action Indicated (OAI). Despite this, Scholar Rock states the FDA review for apitegromab remains on track for the September 30 PDUFA date, utilizing a second, compliant fill-finish facility, mitigating immediate approval risk but highlighting supply chain vulnerabilities.
Scholar Rock announced that it is removing Catalent Indiana as a fill-finish facility from its apitegromab BLA after Catalent received an Official Action Indicated (OAI) classification from the FDA. This is significant because an OAI typically indicates serious compliance issues that could delay or prevent drug approval if not resolved. However, Scholar Rock had proactively included a second fill-finish facility in its BLA, which has already been reviewed by the FDA and is in good standing, allowing the BLA review to remain on track for the September 30 PDUFA date. This development is a near-term neutral for SRRK as the approval timeline is maintained, but it highlights the importance of robust supply chain planning and the potential for manufacturing issues to impact drug launches. For traders, the key takeaway is that the immediate risk of a PDUFA delay due to manufacturing has been largely averted, but investors should monitor any future updates regarding the second facility or potential long-term implications of the Catalent OAI for other products.